tbuckley/cabot-search huggingface dataset:
Interpregnancy interval following miscarriage and adverse pregnancy outcomes: systematic review and meta-analysis
Authors: Chrishny Kangatharan, Saffi Labram, Sohinee Bhattacharya
Journal: Human Reproduction Update (2016)

A short interpregnancy interval (IPI) following a delivery is believed to be associated with adverse outcomes in the next pregnancy. The optimum IPI following miscarriage is controversial. Based on a single large-scale study in Latin and South America, the World Health Organization recommends delaying pregnancy for 6 months after a miscarriage to achieve optimal outcomes in the next pregnancy.Our aim was to determine if a short IPI (<6 months) following miscarriage is associated with adverse outcomes in the next pregnancy.Studies were retrieved from MEDLINE, Embase and Pubmed, with no time and language restrictions. The search strategy used a combination of Medical Subject Headings terms for miscarriage, IPI and adverse outcomes. Bibliographies of the retrieved articles were also searched by hand. All studies including women with at least one miscarriage, comparing subsequent adverse pregnancy outcomes for IPIs of less than and more than 6 months were included. Two independent reviewers screened titles and abstracts for inclusion. Characteristics of the studies were extracted and quality assessed using Critical Appraisal Skills Programme criteria. A systematic review and meta-analysis were conducted to compare short (<6 months) versus long (>6 months) IPI following miscarriage in terms of risk of further miscarriage, preterm birth, stillbirth, pre-eclampsia and low birthweight babies in the subsequent pregnancy. Review Manager 5.3 was used for conducting meta-analyses.Sixteen studies including 1 043 840 women were included in the systematic review and data from 10 of these were included in one or more meta-analyses (977 972 women). With an IPI of less than 6 months, the overall risk of further miscarriage (Risk ratio (RR) 0.82 95% CI 0.78, 0.86) and preterm delivery (RR 0.79 95% CI 0.75, 0.83) were significantly reduced. The pooled risks of stillbirth (RR 0.88 95% CI 0.76, 1.02); low birthweight (RR 1.05 95% CI 0.48, 2.29) and pre-eclampsia (RR 0.95 95% CI 0.88, 1.02) were not affected by IPI. Similar findings were obtained in subgroup analyses when IPI of <6 months was compared with IPI of 6-12 months and >12 months.This is the first systematic review and meta-analysis providing clear evidence that an IPI of less than 6 months following miscarriage is not associated with adverse outcomes in the next pregnancy. This information may be used to revise current guidance.
Evaluation of Human and Rhesus CD34+CXCR4+ and CD34+CXCR4- Subpopulations
Authors: Naoya Uchida, Yu Tian, Ping Jin, Aylin C. Bonifacino, Mark E. Metzger, David Stroncek, John F. Tisdale, Robert E. Donahue
Journal: Blood (2011)
TP53 mutations and Polymorphisms in Primary Myelofibrosis,
Authors: Sania S Raza, David Viswanatha, Lori A Erickson, Terra L Lasho, Christy Finke, Ryan A Knudson, Rhett Ketterling, Animesh D. Pardanani, Ayalew Tefferi
Journal: Blood (2011)
PTU-051 Iatrogenic Hypokalaemia in Acute Severe Colitis
Authors: C Harrington, L Smith, J Munro, S Laird, A Cahill, D Gaya, A Morris, J Winter
Journal: Gut (2016)

<h3>Introduction</h3> Intravenous corticosteroids have been established as the mainstay treatment of acute severe colitis since 1974.<sup>1</sup> BSG and ECCO guidelines advise either IV hydrocortisone 100 mg qds or IV methylprednisolone 30 mg bd in this setting.<sup>2,3</sup> The potent mineralocorticoid effect of hydrocortisone however is well known.<sup>4</sup> This could predispose to hypokalaemia in this susceptible patient cohort. For this reason, we have recently changed our practice at Glasgow Royal Infirmary (GRI) to treat these patients with methylprednisolone. <h3>Methods</h3> We performed a retrospective review of electronically held records of patients who presented to GRI with acute severe colitis treated with IV hydrocortisone or methylprednisolone. We collected data on the duration of treatment, potassium level on presentation, nadir potassium level, fall in potassium level and potassium replacement per patient. <h3>Results</h3> 20 patients were treated with IV hydrocortisone for a median of 6 days, and 16 patients were treated with IV methylprednisolone for a median of 5.5 days (ns). Median serum potassium concentration on admission was 3.8 mol/l (IQR 3.4–4.1 mmol/l) in the cohort receiving hydrocortisone which was not significantly different from 4.1 mmol/l (IQR 3.7–4.1 mol/l) in the cohort receiving methylprednisolone. Following IV steroids, median nadir potassium concentration in the group receiving methylprednisolone was 3.75 mmol/l (IQR 3.5–4.1 mmol/l), not significantly different to pre-treatment values. In those receiving hydrocortisone however, potassium concentration fell by a median of 0.85 mol/l (IQR 0.2–1.1 mol/l) to a nadir of 3.1 mol/l (IQR 2.8–3.3 mol/l), significantly lower than the group receiving methylprednisolone (p &lt; 0.0001). Only 3/16 (19%) patients receiving methylprednisolone needed potassium supplementation (2 oral and one IV). In contrast only 2/20 patients receiving hydrocortisone did not require potassium supplementation, with 10/20 (50%) requiring a median of 80 mmoles of IV potassium chloride (IQR 55–196 mmoles) and 8/20 (40%) requiring oral supplementation. 2 patients receiving hydrocortisone experienced severe hypokalaemia with ECG changes requiring management in the coronary care unit. <h3>Conclusion</h3> Hypokalaemia is a common occurrence in patients with acute severe colitis treated with IV hydrocortisone but is rare when methylprednisolone is used. Given that both drugs are considered to be equally effective, methylprednisolone appears to be a safer choice of corticosteroid. <h3>References</h3> 1 Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. <i>Lancet</i> 1974;<b>1</b>:1067–1070. 2 BSG Guidelines for management IBD 2011. 3 ECCO consensus guidelines for UC 2012. 4 Ramsahoye BH, Davies SV, <i>et al</i>. The mineralocorticoid effects of high dose hydrocortisone. <i>BMJ</i> 1995;<b>310</b>:656. <h3>Disclosure of Interest</h3> None Declared
CD14 <sup>+</sup> monocyte‐derived galectin‐9 induces natural killer cell cytotoxicity in chronic hepatitis C
Authors: Akira Nishio, Tomohide Tatsumi, Takatoshi Nawa, Takahiro Suda, Teppei Yoshioka, Yoshiki Onishi, Satoshi Aono, Minoru Shigekawa, Hayato Hikita, Ryotaro Sakamori, Daisuke Okuzaki, Takasuke Fukuhara, Yoshiharu Matsuura, Naoki Hiramatsu, Tetsuo Takehara
Journal: Hepatology (2016)

Natural killer (NK) cell activation is associated with both liver injury and persistent infection in chronic hepatitis C (CHC); however, the detailed mechanism of this activation has not yet been fully elucidated. Because galectin-9 (Gal-9) has been reported to be increased in the serum and liver tissue of CHC patients, we investigated the function of Gal-9 in NK cell activation in CHC. First, we evaluated the function of Gal-9 on NK cytotoxicity in vitro. Gal-9 treatment resulted in increased cytotoxicity of naïve NK cells, and the Gal-9-activated NK cells demonstrated cytotoxicity toward hepatoma cells and T cells. Additionally, coculturing peripheral blood mononuclear cells (PBMCs) with JFH-1/Huh7.5.1 cells increased both Gal-9 production and NK cell cytotoxicity. Next, we investigated the source of Gal-9 and the mechanism of Gal-9 production. Deletion of CD14+ monocytes from PBMCs resulted in reduced Gal-9 production in the coculture with JFH-1/Huh7.5.1 cells. Gal-9 production was driven by coculturing of PBMCs with apoptotic hepatocytes. Blocking integrin αv β3 , a receptor for phosphatidylserine expressed on apoptotic cells, also resulted in decreased Gal-9 production. Finally, we found that serum Gal-9 levels were significantly higher in CHC patients than in healthy donors and patients who achieved sustained virologic response. Among CHC patients, serum Gal-9 levels were significantly higher in patients with elevated alanine aminotransferase (ALT) than in those with normal ALT.These results demonstrate that CD14+ monocyte-derived Gal-9 increases NK cell cytotoxicity in HCV infection, which might be associated with liver injury and persistent infection. (Hepatology 2017;65:18-31).
Final Analysis of a Phase II Study of Intrapatient Dose-Escalation of Eltrombopag in Patients Receiving Azacitidine for Myelodysplasia/AML
Authors: Michael J. Dickinson, Kirsten Herbert, Caroline Sardjono, Thao Le, Diana Zannino, Colin Wood, John F Seymour, Melita Kenealy, Miles Prince
Journal: Blood (2014)
Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM Study
Authors: Francois-Xavier Mahon, Delphine Rea, Joelle Guilhot, Francois Guilhot, Françoise Huguet, Franck E. Nicolini, Laurence Legros, Aude Charbonnier, Agnès Guerci, Bruno R. Varet, Gabriel Etienne, Josy Reiffers, Philippe Rousselot
Journal: Blood (2011)
Assessment Levels of Factor VIII and IX Inhibitors in Patients with Hemophilia in North West of Iran: What Is the Main Reason of Low Inhibitor Titer and Rate in Our Patients?
Authors: Roya Dolatkhah, Ali Akbar Movasaghpour Akbari, Iraj Asvadi Kermani, Zohreh Sanaat, Azim Rezamand, Fateme Nemati, Hosein Nikkhah
Journal: Blood (2011)
CDK4 and CDK6 Inhibition in Breast Cancer — A New Standard
Authors: Antonio C. Wolff
Journal: New England Journal of Medicine (2016)

Breast cancer is the most prevalent type of malignant neoplasm worldwide, and estrogen-receptor (ER)–positive breast cancer is the most common phenotype. Outcomes continue to improve, but many patients present with advanced disease or have recurrence of disease that progressively becomes resistant to endocrine therapy. Efforts to enhance responsiveness to treatment and to overcome primary or acquired resistance through cotargeting of estrogen and cell proliferation–survival signaling pathways led to the recent approval of phosphatidylinositol 3-kinase–Akt–mammalian target of rapamycin (PI3K/Akt/mTOR) and cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors for the treatment of advanced ER-positive, human epidermal growth factor receptor 2 . . .
Factors Predicting the Outcome of the Blood and Marrow Transplant Patients Admitted to Intensive Care Unit.
Authors: Nalini K Pati, Biju George, Ian Kerridge, Nicole Gilroy, Vineet Nayyar, Eddie Stachowski, Mary McGurgan, Gillian Huang, Kenneth F Bradstock, David J Gottlieb, Mark Hertzberg
Journal: Blood (2009)
HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma
Authors: Guang Yang, Sara Buhrlage, Li Tan, Xia Liu, Jie Chen, Zachary Hunter, Lian Xu, Nicholas Tsakmaklis, Jiaji Chen, Christopher J Patterson, Jorge J Castillo, Wei Zhang, Nathanael Gray, Steven P Treon
Journal: Blood (2015)
Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era
Authors: James R Cerhan, Grzegorz S. Nowakowski, Matthew J Maurer, Bridget Charbonneau, Herve Ghesquieres, Anne J. Novak, Yan W Asmann, Ahmet Dogan, Svetomir N. Markovic, Carrie A. Thompson, Stephen M. Ansell, George J. Weiner, Brian K Link, Thomas M Habermann, Susan L Slager
Journal: Blood (2012)
Reported Versus “Real” Incidence of New Pacemaker Implantation Post-Transcatheter Aortic Valve Replacement
Authors: Chekrallah Chamandi, Ander Regueiro, Vincent Auffret, Tania Rodriguez-Gabella, Olivier Chiche, Alberto Barria, Mélanie Côté, François Philippon, Rishi Puri, Josep Rodés-Cabau
Journal: Journal of the American College of Cardiology (2016)
Lack of Detection of FIP1L1-PDGFRA Gene Fusion in a Cohort of Mastocytosis with Eosinophilia.
Authors: Stephane Barete, Frederic Feger, Eric Delabesse, Olivier Lortholary, Philippe Casassus, Michel Arock, Fabienne Palmerini, Parice Dubreuil, Christian de Gennes, Camille Frances, Elisabeth A. Macintyre, Olivier Hermine
Journal: Blood (2005)
The Medicinal and Antitumor Mushroom, Agaricus Blazei Murill, Activates NF-κB Via TLR2 but Not TLR4 In Monocytic Cells, and Stimulates Monocyte-Derived Dendritic Cells (MDDC) to Increased Cell Surface Marker Expression and Cytokine Production, and May Thus Have Adjuvant Effect In MDDC Cancer Vaccines
Authors: Geir Hetland, Anne Merete Aaland Tryggestad, Terje Espevik, Liv Ryan, Jon-Magnus Tangen, Egil Johnson, Gunnar Kvalheim
Journal: Blood (2010)
Exercise prescription is not just for medical doctors: the benefits of shared care by physicians and exercise professionals
Authors: Andrew Maiorana, Itamar Levinger, Kade Davison, Neil Smart, Jeff Coombes
Journal: British Journal of Sports Medicine (2016)

As allied health professionals, we commend the Canadian Academy of Sport and Exercise Medicine (CASEM) on their recent position statement to better equip physicians for physical activity prescription.1 The CAESM call on physicians to be more engaged in physical activity prescription to reduce the burden of non-communicable diseases associated with physical inactivity. Physicians are uniquely positioned in healthcare systems to improve population levels of physical activity. Most people visit a physician at least annually, and physician advice remains influential in guiding patient behaviour. For example, a simple physical activity counselling intervention by general practitioners significantly reduced inactivity.2

A key objective of the Exercise is Medicine initiative http://www.exerciseismedicine.org/ is for physicians to assess and record physical activity during every patient visit, similar to a vital sign and to facilitate an exercise prescription. However, despite the acknowledged intentions of the CAESM statement, many physicians will remain ill-equipped, or simply not have time, to deliver individualised exercise prescriptions to patients across the …
Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension
Authors: Christopher J. Rhodes, Pavandeep Ghataorhe, John Wharton, Kevin C. Rue-Albrecht, Charaka Hadinnapola, Geoffrey Watson, Marta Bleda, Matthias Haimel, Gerry Coghlan, Paul A. Corris, Luke S. Howard, David G. Kiely, Andrew J. Peacock, Joanna Pepke-Zaba, Mark R. Toshner, S. John Wort, J. Simon R. Gibbs, Allan Lawrie, Stefan Gräf, Nicholas W. Morrell, Martin R. Wilkins
Journal: Circulation (2016)

Background: Pulmonary arterial hypertension (PAH) is a heterogeneous disorder with high mortality. Methods: We conducted a comprehensive study of plasma metabolites using ultraperformance liquid chromatography mass spectrometry to identify patients at high risk of early death, to identify patients who respond well to treatment, and to provide novel molecular insights into disease pathogenesis. Results: Fifty-three circulating metabolites distinguished well-phenotyped patients with idiopathic or heritable PAH (n=365) from healthy control subjects (n=121) after correction for multiple testing ( P &lt;7.3e-5) and confounding factors, including drug therapy, and renal and hepatic impairment. A subset of 20 of 53 metabolites also discriminated patients with PAH from disease control subjects (symptomatic patients without pulmonary hypertension, n=139). Sixty-two metabolites were prognostic in PAH, with 36 of 62 independent of established prognostic markers. Increased levels of tRNA-specific modified nucleosides (N2,N2-dimethylguanosine, N1-methylinosine), tricarboxylic acid cycle intermediates (malate, fumarate), glutamate, fatty acid acylcarnitines, tryptophan, and polyamine metabolites and decreased levels of steroids, sphingomyelins, and phosphatidylcholines distinguished patients from control subjects. The largest differences correlated with increased risk of death, and correction of several metabolites over time was associated with a better outcome. Patients who responded to calcium channel blocker therapy had metabolic profiles similar to those of healthy control subjects. Conclusions: Metabolic profiles in PAH are strongly related to survival and should be considered part of the deep phenotypic characterization of this disease. Our results support the investigation of targeted therapeutic strategies that seek to address the alterations in translational regulation and energy metabolism that characterize these patients.
AB0130 Expression of Regulatory B Cells in Peripheral Blood of Patients with Systemic Lupus Erythematosus
Authors: C. Xiaoyan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> It is generally considered that B cells regulate immune response mainly through producing specific antibodies or a variety of cytokines., but recent studies have found that the lack of B cells and CDl9 –/– mice in experimental autoimmune encephalomyelitis (EAE) mouse model is more serious, and in T cell mediated inflammation experiment, CDl9–/– mice show a more serious contact hypersensitivity (CHS). Therefore, it indicated that B cells also play an important role in the negative immune regulation. <h3>Objectives</h3> To investigate the expression of regulatory B cells (Bregs) in peripheral blood of patients with systemic lupus erythematosus (SLE) and the function of Bregs in the pathogenesis of SLE. <h3>Methods</h3> Thirty-eight active SLE patients, twenty-two inactive SLE patients and twenty healthy controls were enrolled in this study. The expression of IL-10<sup>+</sup>CD19<sup>+</sup>Breg and CD19<sup>+</sup>CD24<sup>hi</sup>CD38<sup>hi</sup>Breg in peripheral blood mononuclear cells (PBMC) was evaluated by flow cytometric analysis. IL-10 was measured in the culture supermatants by ELISA. <h3>Results</h3> The expression of IL-10<sup>+</sup>CD19<sup>+</sup>Breg in PBMCs of active SLE patients was 1.54±0.64%, lower than those in inactive SLE patients (2.42±0.75)% (<i>P</i>&lt;0.001) and healthy controls (4.35±1.00)% (<i>P</i>&lt;0.001). And the expression of CD19<sup>+</sup>CD24<sup>hi</sup>CD38<sup>hi</sup>Breg was 1.26±0.45%, also lower than those in inactive SLE patients (2.01±0.61)% (<i>P</i>&lt;0.001) and healthy controls (3.14±0.87)% (<i>P</i>&lt;0.001). The level of IL-10 in the culture supermatants of active SLE patients significantly decreased, which was lower than those in inactive SLE patients (<i>P</i>&lt;0.05) and healthy controls (<i>P</i>&lt;0.001). The percentage of IL-10<sup>+</sup>CD19<sup>+</sup>Breg and CD19<sup>+</sup>CD24<sup>hi</sup>CD38<sup>hi</sup>Breg in peripheral blood of SLE patients was positively correlated with the level of IL-10 in the culture supermatants (r=0.652, <i>P</i>&lt;0.001 and r=0.574,<i>P</i>&lt;0.001). <h3>Conclusions</h3> Expression of IL-10 related Bregs was significantly decreased in peripheral blood of active SLE patients. Bregs may play a critical role in the pathogenesis of SLE. <h3>Disclosure of Interest</h3> None declared
A Functional Promoter Polymorphism (−8C&amp;gt;G) of the Proteasome Subunit α6 Gene Is Associated with Multiple Myeloma and Poor Outcome Independent of Circulating Proteasome Serum Levels.
Authors: Hagen S Bachmann, Juergen Novotny, Stephan Sixt, Peter Liebisch, Ulrich Frey, Juergen Peters, Ulrich Duehrsen, Winfried Siffert, Holger Nückel
Journal: Blood (2008)
Effects of Dabigatran and Rivaroxaban On Routine and Specialized Coagulation Assays: A Study Using Actual Patient Plasma Samples
Authors: Tyler W. Smith, Leslie Zypchen, Cedric J. Carter, Annie Tran, Pamela Colley, Kenneth Gin, Philip Teal, Bassam A. Masri, Agnes Y.Y. Lee
Journal: Blood (2012)
PTU-140 Exciting the Human Swallowing Motor System by Combination Stimuli: Effects of Pharyngeal Stimulation and Carbonated Liquids
Authors: J Magara, E Michou, M Inoue, S Hamdy
Journal: Gut (2016)

<h3>Introduction</h3> Previous reports have revealed that excitation of human pharyngeal motor cortex can be induced by pharyngeal electrical stimulation (PES)<sup>1 </sup>and swallowing carbonated water (CW).<sup>2</sup> This study is aimed to investigate whether synchronously combining PES with swallowing (of still water, SW or CW) can potentiate this excitation in pharyngeal cortical area and brainstem. Our hypothesis was that combining inputs would potentiate cortico-pharyngeal excitability compared to each alone which would be more advantageous in the rehabilitation of dysphagic patients. For the evaluation of the excitation in pharyngeal cortex or brainstem, Transcranial or transcutaneous Magnetic Stimulation (TMS) was used to stimulate the corticobulbar and craniobulbar neural networks. <h3>Methods</h3> Fourteen healthy volunteers (4 females, age range 19–35 yrs) participated and were intubated with an intraluminal catheter for delivering PES and recording pharyngeal electromyography. Each participants underwent the baseline corticobulbar, craniobulbar and hand motor evoked potential (MEP) measurements with TMS. Subjects were then randomised to receive one of four 10 minute interventions (PES only, ShamPES+CW, PES+CW and PES+SW). Corticobulbar, craniobulbar and hand MEPs were then re-measured for up to 60 minutes. Data were analysed using ANOVA and post hoc t-tests. <h3>Results</h3> Two way rmANOVA comparing pharyngeal MEP amplitude changes in the dominant hemisphere for Interventions×Time showed a significant interaction, F(15, 195) =2.826, P &lt; 0.01. One-way ANOVA for each Interventions indicated significant changes for PES only (P &lt; 0.01) and Sham PES+CW (P &lt; 0.05) but not for PES+CW or PES+SW over time. Subsequent post hoc t-tests with Bonferroni correction showed the main increase took place at the immediate follow-up for Sham PES+CW (**P &lt; 0.01) and at 45 and 60 minutes for the PES only intervention (*P &lt; 0.05) (Fig). One-way ANOVA for each interventions comparing excitability in the brainstem circutry indicated significant amplitude changes only for PES+CW (P &lt; 0.05). <h3>Conclusion</h3> Of the interventions applied, only PES alone was able to induce sustained changes in pharyngeal cortical excitability that built up over time. By contrast, combination stimuli were less effective in promoting enhanced cortical excitability. Of interest, combination stimuli did produce short-term increases in excitability in brain stem reflexes. Our data suggest that PES alone may be most advantageous in dysphagic patients who have a difficulty in performing voluntary swallows. <h3>References</h3> 1 Fraser, <i>et al</i>. <i>Neuron</i> 2002; <b>34</b>:831–40. 2 Elshukri, <i>et al</i><i>. J Appl Physiol</i><b>2016</b>; 15;120:408–15. <h3>Disclosure of Interest</h3> None Declared